Drug Metabolism/Pharmacology News

A 2011 FDA mandate, which limited acetaminophen dosage to 325 mg/tablet in prescription acetaminophen and opioid products, correlated with a decrease in yearly hospitalizations and cases of acute liver failure related to toxicity.

Use of the investigational microbiome therapeutic SER-109 resulted in rapid and steady improvement in disease-specific quality of life for patients with recurrent Clostridioides difficile infection, according to data in JAMA Network Open.

Antibiotic prophylaxis failed to reduce the incidence of hospital-acquired infections or overall mortality among patients with decompensated cirrhosis, according to data published in The American Journal of Gastroenterology.

Direct-acting antiviral treatment significantly lowered the risk for mortality and liver and non-liver outcomes in patients with chronic hepatitis C virus infection, regardless of disease stage, researchers reported.

LONDON — Resmetirom was safe and well tolerated at 100 mg and 80 mg doses in patients with nonalcoholic steatohepatitis, according to late-breaking research presented at the International Liver Congress.

LONDON — Exposure to proton pump inhibitors correlated with an increased risk for severe infection and cirrhosis decompensation among a subset of patients with cirrhosis, according to research presented at the International Liver Congress.

LONDON — Combined glecaprevir and pibrentasvir with ezetimibe prevented hepatitis C infection among patients who received non-liver solid organ transplants with HCV viremic grafts, according to research.

LONDON — Bulevirtide induced a greater combined virologic and biochemical response compared with control at 48 weeks in patients with chronic hepatitis D infection, according to research.

LONDON — Long-term givosiran treatment provided sustained benefit and improved quality of life among patients with acute hepatic porphyria, according to research presented at the International Liver Congress.

Orphalan announced FDA approval of Cuvrior for the treatment of adults with stable Wilson’s disease who are de-coppered and tolerant to penicillamine, according to a company press release.